Abstract
Main regulators of breast metabolism are estradiol, progesterone, prolactin, growth hormone, and insulin-like growth factor 1 (IGF-1) [1]. They control cell function, proliferation, and differentiation activating intracellular signaling cascade (Erk, Akt, JNK, and Ark/Stat) of breast tissue [2]. Estrogen receptor (ER) expression in the breast is stable and differs relatively little in correlation with reproductive status, menstrual cycle phase, or exogenous hormones [3]. Estrogens have apocrine, paracrine, and intercrine effects. Receptors for estradiol are present in fibroblast, epithelial cells, adipocytes, and stromal tissue. Intramammary concentration of estradiol is 20 times higher compared to the level in the blood. Estradiol increases number of progesterone receptors, epithelial proliferation in the luteal phase, galactophore differentiation, connective tissue development, and growth hormone.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hynes NE, Watson CJ. Mammary gland growth factors: roles in normal development and in cancer. Cold Spring Herb Perspect Bio. 2010;2:8–11.
Rawlings JS, Rosler KM, Harrison DA. The JAK/STST signaling pathway. J Cell Sci. 2004;117:1281–3.
Haslam S, Osuch J. Hormones and breast cancer in postmenopausal women. Breast Dis. 2006;42:69.
Houdebine LM. Djiane J, Dusanter-Fourt et al.Hormonal action controlling mammary activity. J Daily Sci. 1985;68:489–560.
Aupperlee MD, Leipprandt JR, Bennet JM, et al. Amphiregulin mediates progesterone induced mammary ductal development during puberty. Breast Cancer Res. 2013;15:44–7.
Diamanti Kandarakis E, Dunaif A. The effects of old, new and emergency medicines on metabolic abberation in PCOS. Endocr Rev 2012; l33:981–1030.
Catsburg C, Gunter M, Chen C, et al. Insulin, estrogen, inflammatory markers and risk of benign proliferative breast disease. Cancer Res. 2014;74:3248–58.
Zhou J, Ng S, Adesanya-Famuiya O, et al. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppress estrogen receptor expression. FASEB J. 2000;14:1725–30.
Welsh J. Vitamin D metabolism in mammary gland and breast cancer. Mol Cell Enbdocrinol. 2011;347:55–60.
Qin W, Smith C, Jensen M, et al. Vitamin D favourably alters the cancer promoting prostaglandin cascade. Anticancer Res. 2013;33:4496–9.
Kahn BB, Flier JS. Obesity and insulin resistance. Clin Invest. 2000;106:473–81.
Genazzani AD, Ricchieri F, Prati A, et al. Differential insulin response to myoinositol administration in obese PCOS patients. Gynecol Endocrinol. 2012;28:969–73.
Slijepcevic D. Stres. Ur. Sekanic D, Kremen, Beograd, 1993.
Pernicova I, Korbonis M. Metforin – mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10:577–86.
Pearce EL. Enhance CD-8 T-cell memory by modulating fatty acid metabolism. Nature. 2009;460:103–7.
Marina LJ, Ivovic M, Vujovic S, et al. Luteinizing hormone and insulin resistance in menopausal patients with adrenal incidentalomas. The cause-effect relationship? Clin Endocrinol. 2018;4:541–8.
Chu DT, Phuong TN. The effect of adipocytes on the regulation of breast in the tumor microinvorenment: an update. Cell. 2019;8:857–60.
Ness J, Sedghinasab M, Moe RE, et al. Identification of multiple proliferative growth factors in breast cyst fluid. Am J Surg. 2014;166:237–43.
Burch JB, Walling M, Rush A, et al. Melatonin and estrogen in breast cyst fluid. Breast Cancer Res Treat. 2007;103:331–41.
Vujovic S. Benign Breast disease during women;s life. In ISGE series: Pre-menopause, menopause and Beyond. Vol 5, Frontiers in Gynecological endocrinology. Editors: Birkhauser M, Genazzani AR, Springer, 2018: 215–221.
Brkic M, Vujovic S, Franic-Ivanisevic M, et al. The influence of progesterone gel therapy in the treatment of fibrocystic breats disease. Open J Obstet Gynecol. 2016;6:334–41.
Foidart JM, Cohn C, Denoo X. Estrogen and progesterone result the proliferation of human breast epithelial cells. Fertil Steril. 1998;69:963–9.
Nappi C, Affinitio PO, Carlo D, et al. Double blind control trial of progesterone vaginal cream treatment of cyclical mastalgia in women with benign breast disease. J Endocrinol Investig. 1992;15:801–6.
Chang KJ, Lee TT, Linares-Cruz G, et al. Et al. influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril. 1995;63:735–91.
Yan W, Zhang Y, Zhao E, et al. Association between the MTHFR C667T polymorphism and breast carcinoma risk: a meta analysis of 23 case control studies. The Breast J. 2016;22:593–4.
Carrol JS, Hickey TE, Tarulli GA, et al. Deciphering the divergent roles of progesterone in breast cancer. Nat Rev Cancer. 2017;17:54–64.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 International Society of Gynecological Endocrinology
About this chapter
Cite this chapter
Vujovic, S. et al. (2021). The Role of Insulin Resistance in Benign Breast Disease. In: Genazzani, A.R., Ibáñez, L., Milewicz, A., Shah, D. (eds) Impact of Polycystic Ovary, Metabolic Syndrome and Obesity on Women Health. ISGE Series. Springer, Cham. https://doi.org/10.1007/978-3-030-63650-0_14
Download citation
DOI: https://doi.org/10.1007/978-3-030-63650-0_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-63649-4
Online ISBN: 978-3-030-63650-0
eBook Packages: MedicineMedicine (R0)